ArticleNatural products and bioprospecting2026
Elucidating therapeutic mechanisms of naringin and phloridzin on ulcerative colitis mice by metabolomics-based comparative analysis.
Article in Natural products and bioprospecting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Naringin and phloridzin are structurally similar flavonoids with anti-inflammatory, antioxidant, and antimicrobial properties, showing considerable potential as natural therapeutic agents. This study demonstrated that naringin and phloridzin exert anti-inflammatory effects and preserve normal intestinal function in UC mice. This protective effect is mediated by inhibition of the NF-κB signalling pathway. To investigate metabolic differences, we employed UPLC-MS/MS-based widely targeted metabolomics alongside targeted analyses of tryptophan (Trp) and short-chain fatty acids (SCFAs). Comparative analysis of metabolic profiles, differential metabolites, and associated pathways revealed regulatory effects on Trp and SCFAs. However, naringin demonstrated superior regulation of Trp metabolism and SCFA levels compared to phloridzin, resulting in more pronounced improvement of gut homeostasis. These findings elucidate the metabolic mechanisms underlying both flavonoid treatments and underscore their potential as complementary therapies for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.